[ad_1]
Improvements in the technologies and models available to investigate and monitor tumour growth should lead to biological insights and might pave the way for the development of more-effective clinical treatments. Writing in Nature, Lorenzo-Martín et al.1 present a system for examining colon cancer.
Competing Interests
N.R. is employed by Genentech, Inc. and owns shares of Roche. F.d.S.e.M. is an employee of Amgen and owns shares of Roche and Amgen.
[ad_2]
Source link
